Mutations on NHR (N-terminal heptad do it again) associated with resistance to fusion inhibitor were observed. the CHR (C34) located near the hydrophobic groove of the NHR. Because the conformational stability of 6-HB is important to HIV-1 infection, we suggested a hypothetical mechanism for the drug resistance: N43D single mutation not only impact the binding of inhibitor, but also affect the affinity between NHR and CHR of gp41, thus may reduce the rate of membrane fusion; compensatory mutation S138A would induce greater hydrophobic RHOC interactions between NHR and CHR, and render the CHR more compatible to NHR than inhibitors. Introduction Human immunodeficiency virus type 1 (HIV-1) is the causative agent of the acquired immunodeficiency syndrome (AIDS). The envelope glycoprotein is involved in HIV-1 infection. It can be made up of two binded subunits noncovalently, gp120 and gp41. The transmembrane subunit gp41, a 345 residues glycoprotein encoded from the gene, comprises three distinct practical domains: a cytoplasm site (residues 705C856), a transmembrane site (TM) (residues 684C705) and an extracellular site. The extracellular site consists of a NHR (N-terminal heptad do it again) theme and a CHR (C-terminal heptad do it again) theme and every three extracelluar domains could associate to create a trimer-of-hairpins. With this trimer-of-hairpins framework, the NHR site forms a central trimeric coiled coil which can be encircled by (three C-peptide areas) CHR site at hydrophobic grooves from the N-trimer. A conformational changeover of trimer-of-hairpins can be mixed up in membrane fusion mediated by gp41. Prior to the fusion, the NHR CHR and site site made up a pre-hairpins, which is meant to be a protracted intermediate framework. Following the conformational changeover, the CHR site can be compressed into -helix combined with the internal trimeric core from the NHR. Eventually, the trimer-of-hairpins can be formed, which is known as as six-helix package (6-HB) [1] also, [2]. This 6-HB is vital for the procedure of HIV-1-mediated membrane fusion,because the NHR site can be proximal towards the fusion peptide (FP) which can be inserted in to the focus on cell membrane, as well as the CHR site can be next to the trans-membrane area of HIV-1 [3]. Fusion inhibitors can be reputed to stop the forming of 6-HB efficiently. Among which, SJ-2176 may be the 1st potent anti-HIV-1 peptide which produced from the CHR site of gp41. SJ-2176 could inhibit the membrane fusion at nanomolar level [4]. After SJ-2176, many peptides derived from NHR domain or CHR domain come up, such as Pimasertib N51 (HIV-1 HXB2 540C590), N36 (HIV-1 HXB2 546C581), N34 (HIV-1 HXB2 546C579), C43 (HIV-1 HXB2 624C666), C34 (HIV-1 HXB2 628C661) and C28 (HIV-1 HXB2 628C655) [5]C[7]. ENF is the first fusion inhibitor that licensed for marketing as antiretroviral drug. It is homologous to Pimasertib gp41 as it mimics 36 amino acids of CHR domain. Recently, it has presented a class of peptide fusion inihibitors with enhanced inhibitory activity. Among them, sifuvirtide (SFT) is a potent inhibitor that has entered the clinical trial stage. It contains 36 amino acids covering Pimasertib part of sequences and structures of native gp41 CHR [8], [9]. D-peptides, which has shown several potential advantages has the capability to become a new class of fusion inhibitors. Its advantages include: resistance to proteolytic degradation, prolonged half-life in serum and reduced immunogenicity in circulation, and possibility for oral administration [10]. Now,the major problem associated with HIV-1 fusion inhibitors is molecular resistance. Fusion inhibitors always lose their effect due to rapid point mutations of the genome of HIV-1. Common mutations have been identified on 6-HB of gp41 and these mutations could attenuate binding affinity and sensitivity of Pimasertib fusion inhibitors in vitro [11]C[13]. However, in return (or on the other hand), these mutations would have unfavorable effects on viral infectivity through interfering with interaction between viral HR1 and HR2 domains [14]. The GIV motif of NHR (L33 to L45) is initially identified ENF (the first fusion inhibitor to prevent the entry of HIV-1) dependent on HIV-1 variant mutation site [15], [16]. Now, many mutations are identified, single mutations like G36D/S, V38A/M, Q40H, N42S/T/D/E, N43D/K/S, L44M and L45M have been generally showed to reduce the sensitivity of ENF [12]. Mutations on gp41 of HIV-1 is thought to reduced the affinity between Pimasertib inhibitors and gp41 by disrupting.